UPDATE: Piper Jaffray Downgrades Pacira Pharmaceuticals Following 2Q13 Net Loss

In a report published Wednesday, Piper Jaffray analyst David Amsellem downgraded Pacira Pharmaceuticals (NASDAQ: PCRX ) from Overweight to Neutral, but raised the price target from $35.00 to $38.00. In the report, Piper Jaffray noted, “Earlier today, Pacira reported a 2Q13 net loss per share of ($0.42), slightly narrower than the